
Ozempic an “epic launch” in India: Novo Nordisk India MD Vikrant Shrotriya
Subscribe to enjoy similar stories. MUMBAI: Danish drugmaker Novo Nordisk launched its blockbuster drug Ozempic in India on Friday, priced at ₹8,800 per monthfor a starting dose. The launch comes close on the heels of Wegovy, the company’s other injectable weight-loss drug, which entered the market in June.
India’s nascent anti-obesity drug market is heating up. Eli Lilly’s Mounjaro has taken an early lead since its March launch, becoming a top-selling drug by October. Novo faces additional competitive pressure next year, as semaglutide—the compound behind Ozempic and Wegovy—loses patent exclusivity in March 2026, paving the way for cheaper domestic generics.
Mounjaro starts at ₹14,000 a month for a 2.5 mg dose, going up to ₹27,500 for a 15 mg dose. After a recent 37% price cut, Wegovy is priced at ₹10,850 for a starting dose, going up to ₹16,400 per month. Mint spoke with Novo Nordisk India managing director Vikrant Shrotriya to understand the company’s strategy.
Edited excerpts: Why launch Ozempic now, and how will it be different from Wegovy? You know the kind of noise Ozempic has created worldwide. It is something we wanted to launch earlier, but we made the choice to launch oral semaglutide (Rybelsus) at that point of time. Then suddenly the demand for Ozempic soared so much that demand was more than the supply.
As the supply normalized we thought of launching Ozempic because we wanted to make sure that we launch with continuous supply. This is not a sudden decision. This is a very well thought through launch process, part of our portfolio strategy, for a flexible approach towards doctors and patients.
Read on livemint.com